Smith Magenis Syndrome and Autism Spectrum Disorders

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-03-30

Study Completion Date

2026-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Autism Spectrum Disorders (ASD) are a neurodevelopmental disorder. Their prevalence is estimated at around 0.4% of the general population worldwide. Their early onset and chronic nature make them a disabling disorder, all the more so as there is a high prevalence of sleep disorders in these populations, estimated at between 50 and 80%, with many complaints of insomnia in particular. These sleep disorders may result from biological, psychological, social, environmental and family factors.

Smith Magenis Syndrome (SMS) is a complex disorder characterized by severe neurological, psychological and behavioral disorders including sleep-wake rhythm disorders. It is a rare disease with a prevalence of 1/25 000.

These sleep disorders observed could be the consequence of a general dysregulation of the circadian system, since SMS patients show an inversion of the melatonin secretion profile (with a totally abnormal diurnal peak) and in patients with autism spectrum disorders, an overall reduction in melatonin secretion.

These sleep-wake disturbances cycle could play a significant role in learning deficits and in the frequency and severity of behavioral abnormalities observed in SMS and ASD.

In this project, investigators propose to study the mechanisms involved in the sleep-wake cycle disorders observed in Smith Magenis and Autism Spectrum children, in particular by evaluating the quality of the pupillary reflex using a pupillometer. The pupillary reflex is a simple and non-invasive method to test light sensitivity and the photobiological mechanisms involved.

In this way, investigators want to evaluate the diurnal profile of the pupillary reflex in children with Smith Magenis syndrome and with Autism Spectrum Disorders in relation to the diurnal melatonin profile.

Investigators will complete this study by determining the chronobiological profile of these patients by measuring different variables:

* Diurnal cortisol and amylase profile
* 24h body temperature and heart rate profile
* Urinary cortisol and 6-sulfatoxymelatonin (major metabolite of melatonin) profiles
* Daytime sleepiness profile measured subjectively by questionnaire and objectively via a waking EEG recording.
* Actimetry at home
* Polysomnography
* A neurocognitive and behavioural assessment

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Sleep Disorders in Specific Learning Disabilities

NCT06878690

Specific Learning Disability Sleep Sleep Disorder (Disorder) +1 more

RECRUITING

Melatonin in Adults With SMS

NCT03492970

Smith Magenis Syndrome

COMPLETED NA

Improving Social Relationships for Adolescents with Central Disorders of Hypersomnolence

NCT06251063

Narcolepsy Type 1 Narcolepsy Type 2 Idiopathic Hypersomnia

RECRUITING NA

Characterization of Children with Complaints of Excessive Daytime Sleepiness

NCT06898008

Excessive Daytime Sleepiness

COMPLETED

Observational Study to Investigate the Melatonin and Cortisol Circadian Rhythms of Individuals With Smith-Magenis Syndrome (SMS)

NCT02180451

Smith Magenis Syndrome

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Smith-Magenis Syndrome Autism Spectrum Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Children with Smith Magenis Syndrome

Group Type OTHER

Assessment

Intervention Type OTHER

Pupil reflex and melatonin profile, circadian profile assessment

Children with Autism Spectrum Disorders

Group Type OTHER

Assessment

Intervention Type OTHER

Pupil reflex and melatonin profile, circadian profile assessment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Assessment

Pupil reflex and melatonin profile, circadian profile assessment

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Genetically confirmed Smith Magenis syndrome (microdeletion of the short arm of chromosome 17 or mutation of the RAI1 gene; obtained by FISH, CGH-array or molecular biology) and children with neuropsychologically confirmed autism spectrum disorder, with no genetic pathology found.
* Aged 5-12 years
* Consent form signed by the parent(s)
* Requiring a sleep assessment in the Hopital Femme Mère Enfant paediatric sleep unit of Pr Franco
* Affiliation to a social security system.

Exclusion Criteria

* Associated ophthalmological disorders that do not allow the photomotor reflex to be studied: optic neuritis, glaucoma and retinitis pigmentosa.
* Algic child (risk of measurement bias: when a patient is in pain his pupils dilate and we observe a greater amplitude in the photomotor reflex), defined by a score on the FPS-R Face Scale \>4/10.

Only for SMS patients:

\- Dyschromatopsia detected in consultation with a rapid Ishihara test adapted to the child's cognitive level, if necessary supplemented by a test performed by ophthalmologists.

Minimum Eligible Age

5 Years

Maximum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No